Clinical trial • Phase III • Infectious Disease|Dermatology
Clinical trial in Skin inflammation
Phase III trial for Skin inflammation. 48 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease|Dermatology
- Trial Disease
- Skin inflammation
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 09-10-2024
- First CTIS Authorization Date
- 10-12-2024
Trial design
Phase III trial across 1 site in Austria.
- Target Sample Size
- 48
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 45
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 48
Austria
- Earliest CTIS Part Ii Submission Date
- 23-10-2024
- Latest Decision Or Authorization Date
- 11-08-2025
- Processing Time Days
- 292
- Number Of Sites
- 1
- Number Of Participants
- 48
Sites
- Site Name
- Medical University Of Vienna
- Department Name
- Department of Clinical Pharmacology
- Principal Investigator Name
- Markus Zeitlinger
- Principal Investigator Email
- markus.zeitlinger@meduniwien.ac.at
- Contact Person Name
- Markus Zeitlinger
- Contact Person Email
- markus.zeitlinger@meduniwien.ac.at
- Number Of Participants
- 48
Sponsor
Primary sponsor
- Full Name
- Medical University Of Vienna
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Austria
Related trials
Other published trials that may interest you.
- KAYVIRUS DSM 33474; KAYVIRUS DSM 33473; PBUNAVIRUS DSM 33593; concentration solution of KAYVIRUS DSM 33473, KAYVIRUS DSM 33474, and PBUNAVIRUS DSM 33593 for Complicated skin wounds (infected wounds) | Staphylococcus aureus wound infection | Pseudomonas aeruginosa wound infection
- PHENOXYMETHYLPENICILLIN for Recurrent Erysipelas in lower limbs
- TERBINAFINE for Distal subungual onychomycosis
- EPROSARTAN MESILATE for Type 2 diabetes
- Aztreonam | Avibactam for Sepsis